Prasinezumab: A New Hope for Parkinson’s Disease?

New research on prasinezumab offers cautious optimism for future Parkinson’s treatments.

Research on new Parkinson’s treatments is advancing, and one of the most talked-about candidates in recent years is prasinezumab. Prasinezumab is a new medicine developed to slow-down the progression of Parkinson's disease. It targets alpha-synuclein — a protein believed to play a key role in Parkinson’s.

In this article, we break down what we currently know from the major PASADENA and PADOVA clinical trials, using clear, accessible language. You will learn:

• How prasinezumab works in the brain and why scientists consider it a promising approach.

• What clinical trials have shown so far — where the treatment did not meet its primary goals and where potential benefits were observed.

• Which motor and non-motor improvements appeared in some patients and in which subgroups these signals were strongest.

• How safe prasinezumab appears to be and which side effects were most common.

• Why a large Phase 3 trial is now being planned, despite mixed results, and what this could mean for the future of Parkinson’s care.

Our goal is to keep you informed with clarity and responsibility — so you understand what science truly shows today, without over-promises, and how these findings might influence everyday life with Parkinson’s.

👉 Read the full detailed guide on prasinezumab here.